Table 1.

Antiviral prophylaxis and treatment in pediatric HSCT recipients (27–35).

Medication	Prophylaxis	Prophylaxis dosea	Treatment	Treatment dosea
Ganciclovir	Y	5 mg/kg/dose IV q24 h	Y	5 mg/kg/dose IV q12 h
Valganciclovir	Y	7 × BSAb × CrClc PO q24 h (max 900 mg/day)	Y	7 × BSAb × CrClc PO q12 h (max: 900 mg/dose)
Foscarnetd	Y	60 mg/kg/dose IV q12 h for 7 days then 90–120 mg/kg/dose qDay	Y	60 mg/kg/dose IV q8 h; Maintenance: 90 mg/kg qDay
Cidofovire	Yf	5 mg/kg/dose qWeek × 2 weeks then 5 mg/kg/dose every other week	Y	5 mg/kg/dose qWeek × 2 weeks then 5 mg/kg/dose every other week
Letermovir (≥18 years)	Y	480 mg PO IV q24 h	N	NA
Maribavir (≥12 years and ≥35 kg)	N	NA	Y	400 mg PO BID

^a Dosing given is for patients with normal renal function.

^b BSA, body surface area.

^c CrCl, creatinine clearance, using modified Schwartz formula which bases k constant on age.

^d IV hydration should be given as 10–20 ml/kg (max 1,000 ml) prior to initial infusion and then 10–20 ml/kg (max 1,000 ml) given concurrently with subsequent doses.

^e Should be given with probenecid (25–40 mg/kg/dose (max 2,000mg) PO 3 h prior to cidofovir and 10–20 mg/kg/dose (max 1,000 mg) 2–3 h and 8–9 h after cidofovir) as well as IV hydration (10–20 ml/kg pre- and post-cidofovir OR increase maintenance IVF by 1.5–2×).

^f Less commonly used due to availability of other agents with more favorable side effect profiles.